Jump to content
Powered by

Selected press releases

  • Press release - 09/12/2015

    High-Tech Gründerfonds (HTGF) is raising its seed investment to €600k and lowering interest rates by 4%. This is in response to changing requirements in the start-up and venture capital scene, as well as current interest rate trends. The package of measures will be effective from January 1, 2016.

  • Press release - 16/11/2015

    (Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany.

  • Press release - 03/11/2015

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

  • Press release - 30/09/2015

    Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period. As a leading contract development and manufacturing organization, Vetter is continuously developing its manufacturing sites and techniques to prepare them for future needs and…

  • Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015

    Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…

  • Press release - 11/09/2015

    Venneos GmbH is based in Stuttgart and develops a novel imaging system for the analysis of biological cells. A consortium of business angels and family offices, along with the High-Tech Gründerfonds and Max Planck Society invest in the company to develop a market-ready product and prepare the market entry of the first product generation.

  • Press release - 24/06/2015

    AK BioRegio, the working group of Germany’s biotechnol-ogy regions, elected the new committee to represent it for the next two years at its meeting in Heidelberg last Tuesday. Dr. Klaus Eichenberg, Managing Director of BioRegio STERN Management GmbH, was re-elected as spokesman, with Dr. Hein-rich Cuypers, Senior Project Manager of BioCon Valley GmbH in Greifswald, con-firmed as his deputy. Dr. Hinrich Habeck, Managing Director of Life Science…

  • Press release - 29/04/2015

    cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.

  • Press release - 01/04/2015

    The slow death of dopamine-producing nerve cells in a certain region of the brain is the principal cause underlying Parkinson's disease. In mice, it is possible to simulate the symptoms of this disease using a substance that selectively kills dopamine-producing neurons. Scientists from the German Cancer Research Center (DKFZ) have now shown for the first time in mouse experiments that after this treatment, cells of the peripheral immune…

  • Press release - 19/03/2015

    The new RNA Bioinformatics Center (RBC) is a joint project of the Universities of Freiburg and Leipzig as well as the Max-Delbrück Center Berlin. It is one of six performance centers selected for funding by the Federal Ministry of Education and Research (BMBF) and will receive 3.3 million euros in the next five years. It is part of the project “German Network for Bioinformatics Infrastructure,” which was launched on 1 March 2015.

  • Press release - 09/03/2015

    Gilead Sciences, Inc. (Foster City, CA, U.S.A.) and Phenex Pharmaceuticals AG (Ludwigshafen/Heidelberg, Germany), a privately-held biotechnology company, announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH).

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release